TY - JOUR AU - Chenggong Li AU - Yigeng Feng PY - 2022/10/10 Y2 - 2024/03/29 TI - Kanglaite upregulates CD4+ T cells by inhibiting the expression of IL-1β in A549 cells JF - STEMedicine JA - STEMedicine VL - 3 IS - 4 SE - Research articles DO - 10.37175/stemedicine.v3i4.149 UR - https://stemedicine.org/index.php/stem/article/view/149 AB - Background: Superior clinical efficacy and safety have been demonstrated in Kanglaite combined with cisplatin compared with cisplatin- or Kanglaite-alone treatment on advanced non-small cell lung cancer (NSCLC). However, the mechanism of how Kanglaite enhances antitumor effect of cisplatin is not fully addressed.Methods: An A549 tumor-bearing mouse model was applied in this study. The tumor-bearing mice were treated with 0.9% saline, Kanglaite-alone, cisplatin-alone, or Kanglaite and cisplatin combination. Immune cell population was determined by flow cytometry assay. The production of cytokine was measured by ELISA assay.Results: The results demonstrated that Kanglaite and cisplatin combination treatment exerted the most potent effects on reducing tumor growth and prolonging mouse survival. Further studies revealed that the upregulation of CD4+ T cells and downregulation of IL-1β might be responsible for the Kanglaite-promoted antitumor effect of cisplatin on A549 tumor.Conclusion: Kanglaite serves as an excellent supplement for cisplatin in treating patients with advanced NSCLC. ER -